DCTH

Insider Trades

Name	Value	Action	Price	Current Price
Pennell SandraChief Financial Officer $50k5.5k shares BuyMar 6, 2026 $9.04 --
Michel Gerard JDirector, Officer: CHIEF EXECUTIVE OFFICER $100k11.2k shares BuyMar 2, 2026 $8.96 --
Sylvester John RichardDirector $39k4.4k shares BuyNov 21, 2025 $8.89 --
Michel Gerard JDirector, Officer: CHIEF EXECUTIVE OFFICER $98k11.5k shares BuyNov 11, 2025 $8.53 --

News

businesswire.comDelcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstractsbusinesswire.comMay 26

gurufocus.comIs Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervaluedgurufocus.comMay 22

businesswire.comDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.comMay 15

businesswire.comDelcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conferencebusinesswire.comMay 12

seekingalpha.comDelcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7

Trade DCTH

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

CEO: Gerard J. Michel
IPO Date: May 3, 2018

Market Data

Open: $12.09
High: $12.18
Low: $11.64
Volume: 518.8K
Avg Volume: 423.8K
52W High: $14.48
52W Low: $8.12

Valuation

Market Cap: $404M
Enterprise Value: $363M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $21M
Revenue: $85M
Net Income: $2.7M
Cash: $43M
Debt: $936k

Events

EarningsAug 5

EPS est. -0.09